Casdin Capital, LLC Q3 2022 vs. Q4 2022 13F Holdings Comparison

Casdin Capital, LLC, a biotech-focused hedge fund, recently filed its Q4 2022 13F report, showing changes in holdings compared to the previous quarter. In this blog post, we will take a closer look at the top holdings of the hedge fund and the significant changes that occurred during the Q3 to Q4 period.

Top Holdings

Casdin Capital's top three holdings remain unchanged from the previous quarter, with Sarepta Therapeutics Inc. (SRPT), Biolife Solutions Inc. (BLFS), and EQRx Inc. (EQRX) holding the first three spots, respectively. With a 25.8% increase in shares held, Sarepta remains the largest position in the fund, with 1.3 million shares worth $170.4 million. Biolife Solutions, with no change in shares held, comes in second with $137.7 million worth of shares. EQRx, on the other hand, saw the number of shares held by the fund decrease significantly from 39.5 million to 39.5 million, with the value of shares held dropping by 50.3%, from $195.7 million to $97.2 million.

Significant Changes

Among the significant changes during the Q3 to Q4 period is Blueprint Medicines Corp. (BPMC), whose position in the fund dropped from 1.7 million shares to 1.5 million shares, a 42.2% decrease. The value of shares held also decreased from $112 million to $64.7 million. The only option type listed in the CSV, Moderna Inc. (MRNA) saw a 180.4% increase in shares held, from 32,500 shares to 60,000 shares. The value of shares held also increased from $3.8 million to $10.8 million.

Other notable changes include a 106.6% increase in shares held for Pliant Therapeutics Inc. (PLRX), from 750,000 to 1,675,000; a 93.8% increase in shares held for 2Seventy Bio Inc. (TSVT), from 614,754 to 1,850,000; and a 74.9% increase in shares held for Twist Bioscience Corp. (TWST), from 365,000 to 945,000.

Conclusion

The changes in the holdings of Casdin Capital, LLC during the Q3 to Q4 period reflect the fund's strategy to focus on biotech and healthcare companies. Despite some significant decreases in holdings in companies like EQRx and Blueprint Medicines, which may indicate a shift in the fund's outlook, the fund also increased its positions in Moderna, Pliant Therapeutics, and other biotech firms. Investors should take note of the recent changes in holdings and consider them when making their investment decisions in the biotech sector.

Note: The holdings listed in this article are based on a public filing with the Securities and Exchange Commission on 02/14/2022. It is important to keep in mind that the holdings may have changed since the filing date.